DSP-0390 for Brain Tumor

Recruiting in Palo Alto (17 mi)

+9 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: Sumitomo Dainippon Pharma Oncology, Inc

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial is testing a new drug called DSP-0390 in patients with a type of brain cancer that has returned after treatment. The goal is to see if this drug can help stop or slow down the cancer.

Research Team

Jian Li, MD

Principal Investigator

Sumitomo Pharma America, Inc.

Eligibility Criteria

This trial is for adults with recurrent high-grade glioma who have a good performance status, stable organ function, and no recent major surgeries or other cancer treatments. They must not have certain heart conditions, active infections (HIV/HCV/HBV), significant eye abnormalities, uncontrolled illnesses that could affect study participation, or be on conflicting medications. Women of childbearing potential and men must agree to use contraception.

Inclusion Criteria

I am mostly able to care for myself and carry out daily activities.

Agreement to use contraception or prevention of pregnancy measures for male or female patients of child-producing potential

I have recovered from previous cancer treatment side effects.

See 5 more

Exclusion Criteria

I haven't had treatments targeting blood vessel growth in the last 3 months.

I have not had lung inflammation or disease in the last 6 months.

I haven't had recent major surgery, brain bleeding, recent chemo or radiotherapy, and I'm not using prohibited meds or Optune.

See 6 more

Treatment Details

Interventions

DSP-0390 (Other)

Trial OverviewThe trial is testing DSP-0390 in patients with recurrent high-grade brain tumors like glioblastoma. It aims to see how effective this drug is in treating the tumor and what side effects it may cause.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Single arm DSP-0390Experimental Treatment1 Intervention

Arm Description \[\*\] DSP-0390 by oral administration